| Name | Oxaliplatin | ||
| PubChem CID | 9887053 | ||
| Molecular Weight | 397.29g/mol | ||
| Synonyms |
oxaliplatin, DTXSID0036760, Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II), cis-oxalato-trans-l-1,2-diaminocyclohexaneplatinum(II), CAS-61825-94-3, Oxaliplatin [USAN:INN:BAN], NCGC00167798-01, SCHEMBL19511, HMS3269F19, Tox21_112585, Tox21_112629, AKOS005766023, AKOS015855804, CS-0992, 1ST11037, BP-25383, HY-17371, NS00075364, [(1S,2S)-2-azanidylcyclohexyl]azanide; oxalate; platinum(4+) |
||
| Drug Type | Small molecule | ||
| Formula | C₈H₁₄N₂O₄Pt | ||
| SMILES | C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2] | ||
| InChI | 1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1 | ||
| InChIKey | DRMCATBEKSVAPL-BNTLRKBRSA-N | ||
| CAS Number | 61825-94-3 | ||
| TTD ID | D0Y3ME | ||
| Drug Bank ID | DB00526 | ||
| KEGG ID | D01790 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Vitamin C, Oxaliplatin | |||
| Partner Name | Vitamin C | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->Oxidative Stress | |||
| Gene Regulation | Up-regulation | Expression | CDH1 | hsa999 |
| Down-regulation | Expression | CDH2 | hsa1000 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| Result | Treatment with the combination of oxaliplatin with vitamin C can inhibit CRC cell growth and decrease cancer cell migration and invasion, via oxidative stress and cadherins. | |||
| Pair Name | Vitamin C, Oxaliplatin | |||
| Partner Name | Vitamin C | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
| Up-regulation | Activity | CASP7 | hsa840 | |
| Up-regulation | Expression | H2AX | hsa3014 | |
| Down-regulation | Expression | SLC2A1 | hsa6513 | |
| In Vitro Model | AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 |
| SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 | |
| HGC-27 | Gastric carcinoma | Homo sapiens (Human) | CVCL_1279 | |
| MGC-803 | Gastric mucinous adenocarcinoma | Homo sapiens (Human) | CVCL_5334 | |
| In Vivo Model | AGS cells (1×10⁷/mice) were subcutaneously inoculated into the right armpit of the nude mice. | |||
| Result | The current study showed that GLUT1 expression was inversely correlated with sensitivity of gastric cancer cells to pharmacological ascorbate and suggested that GLUT1 expression in gastric cancer may serve as a marker for sensitivity to pharmacological ascorbate. | |||
| Pair Name | Ursolic acid, Oxaliplatin | |||
| Partner Name | Ursolic acid | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | BIRC5 | hsa332 |
| Up-regulation | Activity | CASP3 | hsa836 | |
| Up-regulation | Activity | CASP8 | hsa841 | |
| Up-regulation | Activity | CASP9 | hsa842 | |
| Down-regulation | Expression | XIAP | hsa331 | |
| In Vitro Model | RKO | Colon carcinoma | Homo sapiens (Human) | CVCL_0504 |
| Result | These observations suggested that a combination of UA and Oxa elicited synergistically anticancer effects in RKO cells and provided new evidence for potential application of UA and Oxa for CRC treatment. | |||
| Pair Name | Sophocarpine, Oxaliplatin | |||
| Partner Name | Sophocarpine | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Biological Phenomena | Inhibition-->Epithelial-mesenchymal transition | |||
| Gene Regulation | Up-regulation | Expression | CDH1 | hsa999 |
| Down-regulation | Expression | CDH2 | hsa1000 | |
| Down-regulation | Expression | VIM | hsa7431 | |
| In Vitro Model | LoVo | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0399 |
| In Vivo Model | Liver metastasis nude mouse models (n = 40) were prepared by the injection of LoVo cells suspended in PBS into the center point of the spleen using a 31-gauge needle. | |||
| Result | Sophocarpine can enhance the inhibiting effect of oxaliplatin on colon cancer liver metastasis-in vitro and in vivo | |||
| Pair Name | Shikonin, Oxaliplatin | |||
| Partner Name | Shikonin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Endoplasmic reticulum stress | |||
| Gene Regulation | Up-regulation | Expression | ROS1 | hsa6098 |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| Result | Our findings imply the potential of SHI to boost the sensitivity of OXA to CRC, offering promising benefits for clinical strategies to combat OXA resistance. | |||
| Pair Name | Scutellarin, Oxaliplatin | |||
| Partner Name | Scutellarin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Mitochondrial apoptosis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Down-regulation | Activity | PKM | hsa5315 | |
| In Vitro Model | SW480 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0546 |
| HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 | |
| Result | It was indicated that scutellarin resensitizes oxaliplatin-resistant CRC cells to oxaliplatin treatment through inhibition of PKM2. | |||
| Pair Name | Rhein, Oxaliplatin | |||
| Partner Name | Rhein | |||
| Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | PIK3CA | hsa5290 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| In Vitro Model | PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 |
| MIA PaCa-2 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0428 | |
| Result | These data demonstrate that Rhein can induce apoptosis and enhance the oxaliplatin sensitivity of PC cells, suggesting that Rhein may be an effective strategy to overcome drug resistance in the chemotherapeutic treatment of PC. | |||
| Pair Name | Quercetin, Oxaliplatin | |||
| Partner Name | Quercetin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| In Vivo Model | To generate HCT116 xenografts in BALB/c nude mice, 3×10⁶ HCT116 cells were subcutaneously injected into the left and right flanks of each mouse. | |||
| Result | These findings suggest that the depletion of intracellular glutathione by quercetin and sulforaphane could strengthen the anti-cancer efficacy of oxaliplatin. | |||
| Pair Name | Platycodin D, Oxaliplatin | |||
| Partner Name | Platycodin D | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Inhibition-->Cell metastasis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Expression | MKI67 | hsa4288 | |
| Up-regulation | Expression | PSMD9 | hsa5715 | |
| Down-regulation | Phosphorylation | WWTR1 | hsa25937 | |
| Down-regulation | Phosphorylation | YAP1 | hsa10413 | |
| In Vitro Model | LoVo | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0399 |
| Result | Our results showed that PD is suitable as a promising agent for overcoming oxaliplatin-resistant colorectal cancer. | |||
| Pair Name | Piperlongumine, Oxaliplatin | |||
| Partner Name | Piperlongumine | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->DNA damage | |||
| Gene Regulation | Up-regulation | Expression | H2AX | hsa3014 |
| Up-regulation | Phosphorylation | MAPK14 | hsa1432 | |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
| BGC-823 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_3360 | |
| In Vivo Model | HCT116 cells (5×10⁶ cells in 100 μl PBS) were harvested and injected subcutaneously into the right flanks of the mice. Next, the mice were divided into four experimental groups on randomization and blinding, with four mice in each group. | |||
| Result | Piperlongumine significantly enhanced oxaliplatin-induced growth inhibition of these cells and that TrxR1 activity is involved in their synergistic effect both in vitro and in vivo. These data suggest that PL and oxaliplatin combination treatment of gastric cancer may be more effective than oxaliplatin alone. | |||
| Pair Name | Piperlongumine, Oxaliplatin | |||
| Partner Name | Piperlongumine | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->Oxidative Stress | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Activity | CASP3 | hsa836 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| LoVo | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0399 | |
| In Vivo Model | For a xenograft model, HCT-116 cells (1×10⁷ in 150 uL PBS) were subcutaneously injected into the right flank of five-week-old female athymic BALB/c nu/nu mice. | |||
| Result | This study provides a novel combination therapy for colorectal cancer, and reveals that manipulating ROS production might constitute an effective tool for developing novel treatments in colorectal cancer. | |||
| Pair Name | Mangiferin, Oxaliplatin | |||
| Partner Name | Mangiferin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
| Down-regulation | Expression | CDH13 | hsa1012 | |
| In Vitro Model | HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 |
| Result | The present study indicates that mangiferin in combination with oxaliplatin favours apoptotic cell death and thereby improves the efficacy of oxaliplatin in vitro. In addition, combination therapy with mangiferin may also counteract the development of resistance in cancer cell lines. | |||
| Pair Name | Luteolin, Oxaliplatin | |||
| Partner Name | Luteolin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Down-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| Up-regulation | Expression | HMOX1 | hsa3162 | |
| Up-regulation | Activity | NFE2L2 | hsa4780 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| Result | Luteolin can induce p53-mediated apoptosis regardless of oxaliplatin treatment and may eliminate oxaliplatin-resistant p53-null colorectal cells | |||
| Pair Name | Luteolin, Oxaliplatin | |||
| Partner Name | Luteolin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
| Result | Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin through the Cyt c/caspase pathway | |||
| Pair Name | Luteolin, Oxaliplatin | |||
| Partner Name | Luteolin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | CCNA2 | hsa890 | |
| Down-regulation | Expression | CCNB1 | hsa891 | |
| Down-regulation | Expression | CD40LG | hsa959 | |
| Down-regulation | Expression | CDC25C | hsa995 | |
| Down-regulation | Expression | CDK1 | hsa983 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| In Vitro Model | MFC | Mouse gastric carcinoma | Mus musculus (Mouse) | CVCL_5J48 |
| Result | Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G2/M cell cycle arrest and apoptosis | |||
| Pair Name | Lentinan, Oxaliplatin | |||
| Partner Name | Lentinan | |||
| Disease Info | [ICD-11: 2B70] | Esophageal cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CALR | hsa811 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Expression | HSP90AA1 | hsa3320 | |
| Up-regulation | Expression | HSPA1A | hsa3303 | |
| In Vitro Model | Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_6898 |
| Result | These data imply that LNT increases the susceptibility of esophageal cancerous cells to Oxa by driving EC-109 cells to display immunogenic death. Therefore, LNT combined with Oxa may be an effective method in esophageal cancer management. | |||
| Pair Name | Honokiol, Oxaliplatin | |||
| Partner Name | Honokiol | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | MAPK1 | hsa5594 | |
| Down-regulation | Expression | MAPK3 | hsa5595 | |
| Down-regulation | Expression | RELA | hsa5970 | |
| In Vitro Model | HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 |
| Result | This combination allows a reduction in oxaliplatin dose, and thereby reduces its adverse effects. It may also enhance the chemotherapeutic effect of oxaliplatin for this disease. | |||
| Pair Name | Genipin, Oxaliplatin | |||
| Partner Name | Genipin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Up-regulation | Expression | DRAM1 | hsa55332 |
| Up-regulation | Expression | MAP1LC3A | hsa84557 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 |
| MKN45 | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0434 | |
| MKN28 | Gastric tubular adenocarcinoma | Homo sapiens (Human) | CVCL_1416 | |
| Result | We showed that genipin increases the oxaliplatin-induced cell death via p53-DRAM autophagy, we suggest that genipin is a sensitizer of oxaliplatin. | |||
| Pair Name | Dihydroartemisinin, Oxaliplatin | |||
| Partner Name | Dihydroartemisinin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Oxidative Stress | |||
| Gene Regulation | Up-regulation | Expression | ATF4 | hsa468 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Phosphorylation | EIF2S1 | hsa1965 | |
| Up-regulation | Expression | MAPK14 | hsa1432 | |
| Up-regulation | Expression | MAPK8 | hsa5599 | |
| Down-regulation | Expression | PRDX2 | hsa7001 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| Down-regulation | Expression | STAT3 | hsa6774 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| RKO | Colon carcinoma | Homo sapiens (Human) | CVCL_0504 | |
| In Vivo Model | The cells were subcutaneously injected into the flanks of nude mice at a concentration of 5×10⁶ cells in 100 μl of PBS/Matrigel mixture (1: 1). | |||
| Result | We demonstrated an improved therapeutic strategy for CRC patients by combining DHA and oxaliplatin treatments. | |||
| Pair Name | Alantolactone, Oxaliplatin | |||
| Partner Name | Alantolactone | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->ROS accumulation | |||
| Gene Regulation | Up-regulation | Phosphorylation | MAPK14 | hsa1432 |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| RKO | Colon carcinoma | Homo sapiens (Human) | CVCL_0504 | |
| In Vivo Model | HCT116 cells (5×10⁶) in 0.1 mL PBS was inject subcutaneously into the right flank of each mouse. | |||
| Result | These results suggest that the combination treatment with ALT and oxaliplatin may become a potential therapeutic strategy for colon cancer. | |||
| Pair Name | Ursolic acid, Oxaliplatin | |||
| Partner Name | Ursolic acid | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->ROS generation | |||
| Gene Regulation | Down-regulation | Expression | ABCB1 | hsa5243 |
| Down-regulation | Expression | ABCC1 | hsa4363 | |
| Up-regulation | Activity | CASP3 | hsa836 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| In Vitro Model | HCT 8 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_2478 |
| SW480 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0546 | |
| Result | Our study provided evidence that ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by ROS-mediated inhibition of drug resistance. | |||
| Pair Name | Luteolin, Oxaliplatin | |||
| Partner Name | Luteolin | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | GABPA | hsa2551 |
| Down-regulation | Expression | GSTA1 | hsa2938 | |
| Down-regulation | Expression | GSTA2 | hsa2939 | |
| Down-regulation | Expression | HMOX1 | hsa3162 | |
| Down-regulation | Expression | NQO1 | hsa1728 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| SW620 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0547 | |
| Result | Adaptive activation of Nrf2 may contribute to the development of acquired drug-resistance and luteolin could restore sensitivity of oxaliplatin-resistant cell lines to chemotherapeutic drugs. Inhibition of the Nrf2 pathway may be the mechanism for this restored therapeutic response. | |||
| Pair Name | Beta-Elemene, Oxaliplatin | |||
| Partner Name | Beta-Elemene | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Cellular uptake | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | BECN1 | hsa8678 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Expression | MAP1LC3A | hsa84557 | |
| Down-regulation | Phosphorylation | MAPK3 | hsa5595 | |
| Up-regulation | Cleavage | PAEP | hsa5047 | |
| In Vitro Model | MHCC97-H | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_4972 |
| HCCLM3 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_6832 | |
| In Vivo Model | Human HCC cell line MHCC97H were used to estabolish xenograft models in the BALB/c mice. | |||
| Result | Our findings show that β-elemene can block the reduction of CTR1 resulting from oxaliplatin treatment, and therefore has a synergistic anti-HCC effect with oxaliplatin by enhancing cellular uptake of oxaliplatin. The synergistic effects of β-elemene and oxaliplatin deserve further evaluation in clinical settings. | |||
| Pair Name | Withaferin A, Oxaliplatin | |||
| Partner Name | Withaferin A | |||
| Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
| Biological Phenomena | Induction-->ROS accumulation | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Phosphorylation | BRAF | hsa673 | |
| Down-regulation | Activity | CASP3 | hsa836 | |
| Up-regulation | Phosphorylation | MAPK14 | hsa1432 | |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Down-regulation | Phosphorylation | PDPK1 | hsa5170 | |
| Down-regulation | Phosphorylation | PIK3R1 | hsa5295 | |
| Down-regulation | Expression | XIAP | hsa331 | |
| In Vitro Model | PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 |
| MIA PaCa-2 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0428 | |
| SW1990 | Pancreatic adenocarcinoma | Homo sapiens (Human) | CVCL_1723 | |
| Result | These results support the notion that combination treatment with oxaliplatin and WA could facilitate development of an effective strategy for PC treatment. | |||
| Pair Name | Rutin, Oxaliplatin | |||
| Partner Name | Rutin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Cleavage | CASP7 | hsa840 | |
| Up-regulation | Cleavage | CASP8 | hsa841 | |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Up-regulation | Phosphorylation | MAPK14 | hsa1432 | |
| In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
| Result | P38 Signal Transduction Pathway Has More Cofactors on Apoptosis of SGC-7901 Gastric Cancer Cells Induced by Combination of Rutin and Oxaliplatin | |||
| Pair Name | Genipin, Oxaliplatin | |||
| Partner Name | Genipin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Endoplasmic reticulum stress | |||
| Gene Regulation | Up-regulation | Expression | BCL2L11 | KEGG ID N.A. |
| Up-regulation | Expression | BIM | hsa10018 | |
| Up-regulation | Expression | ESR1 | hsa2099 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| Down-regulation | Activity | SOD3 | hsa6649 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| DLD-1 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0248 | |
| Result | These findings suggest that genipin may be a novel agent for increasing the sensitivity of oxaliplatin against colorectal cancer. The combination of oxaliplatin and genipin hold significant therapeutic potential with minimal adverse effects. | |||
| Pair Name | Beta-Cryptoxanthin, Oxaliplatin | |||
| Partner Name | Beta-Cryptoxanthin | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | TP73 | hsa7161 |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| SW1417 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_1717 | |
| In Vivo Model | 1×10⁶ HCT116 cells and 1×10⁶ and 107 SW480 cells suspended in 20% matrigel were subcutaneously injected to nude mice (Hsd:Athymic Nude-Foxn1nu, female, 6 weeks old). | |||
| Result | We propose a putative novel therapeutic strategy for the treatment of colon cancer based on the combination of β-cryptoxanthin and oxaliplatin. The combined regimen produced more benefit than either individual modality without increasing side effects. In addition, the concentration-limiting toxicity of oxaliplatin is reduced in the presence of the carotenoid. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells. Cancer Lett. 2015 Feb 1;357(1):219-230. doi: 10.1016/j.canlet.2014.11.026. | Click |
| 2 | P38 Signal Transduction Pathway Has More Cofactors on Apoptosis of SGC-7901 Gastric Cancer Cells Induced by Combination of Rutin and Oxaliplatin. Biomed Res Int. 2019 Nov 6;2019:6407210. doi: 10.1155/2019/6407210. | Click |
| 3 | Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer. Mol Cancer Ther. 2019 Apr;18(4):751-761. doi: 10.1158/1535-7163.MCT-18-0196. | Click |
| 4 | β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer. Clin Cancer Res. 2015 Oct 1;21(19):4398-409. doi: 10.1158/1078-0432.CCR-14-2027. | Click |
| 5 | Vitamin C Improves the Inhibitory Effects of Oxaliplatin on HCT-116 Colorectal Cancer Growth and Progression Through Cellular Oxidant Function-associated Cadherin Molecules. Anticancer Res. 2023 Oct;43(10):4461-4472. doi: 10.21873/anticanres.16641. | Click |
| 6 | Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation. Theranostics. 2018 Feb 2;8(5):1312-1326. doi: 10.7150/thno.21745. | Click |
| 7 | Ursolic acid potentiated oxaliplatin to induce apoptosis in colorectal cancer RKO cells. Pharmazie. 2020 Jun 1;75(6):246-249. doi: 10.1691/ph.2020.0417. | Click |
| 8 | Sophocarpine can enhance the inhibiting effect of oxaliplatin on colon cancer liver metastasis-in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2021 Jun;394(6):1263-1274. doi: 10.1007/s00210-020-02032-8. | Click |
| 9 | Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells. Drug Dev Res. 2023 May;84(3):542-555. doi: 10.1002/ddr.22044. | Click |
| 10 | Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2. Mol Ther Oncolytics. 2021 Mar 17;21:87-97. doi: 10.1016/j.omto.2021.03.010. | Click |
| 11 | Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cells. Int J Biol Sci. 2021 Jan 15;17(2):589-602. doi: 10.7150/ijbs.49514. | Click |
| 12 | Quercetin-Induced Glutathione Depletion Sensitizes Colorectal Cancer Cells to Oxaliplatin. Foods. 2023 Apr 21;12(8):1733. doi: 10.3390/foods12081733. | Click |
| 13 | Platycodin D confers oxaliplatin Resistance in Colorectal Cancer by activating the LATS2/YAP1 axis of the hippo signaling pathway. J Cancer. 2023 Jan 22;14(3):393-402. doi: 10.7150/jca.77322. | Click |
| 14 | Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells. Cell Oncol (Dordr). 2019;42(6):847-860. doi:10.1007/s13402-019-00471-x | Click |
| 15 | The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death Dis. 2019 Aug 8;10(8):600. doi: 10.1038/s41419-019-1824-6. | Click |
| 16 | Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFκB in cancer cell lines. Afr J Tradit Complement Altern Med. 2011;8(2):177-84. doi: 10.4314/ajtcam.v8i2.63206. | Click |
| 17 | Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells. Nutrients. 2019 Apr 2;11(4):770. doi: 10.3390/nu11040770. | Click |
| 18 | Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin. Biomed Res Int. 2020 Feb 21;2020:9396512. doi: 10.1155/2020/9396512. | Click |
| 19 | Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G2/M cell cycle arrest and apoptosis. Oncol Lett. 2022 Jan;23(1):16. doi: 10.3892/ol.2021.13134. | Click |
| 20 | Lentinan Enhances the Function of Oxaliplatin on the Esophageal Tumors by Persuading Immunogenic Cell Death. Comput Math Methods Med. 2023 Oct 4;2023:9827631. doi: 10.1155/2023/9827631. | Click |
| 21 | Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):773-9. doi: 10.1093/abbs/gmt071. | Click |
| 22 | Genipin increases oxaliplatin-induced cell death through autophagy in gastric cancer. J Cancer. 2020 Jan 1;11(2):460-467. doi: 10.7150/jca.34773. | Click |
| 23 | Dihydroartemisinin enhances the anti-tumor activity of oxaliplatin in colorectal cancer cells by altering PRDX2-reactive oxygen species-mediated multiple signaling pathways. Phytomedicine. 2022 Apr;98:153932. doi: 10.1016/j.phymed.2022.153932. | Click |
| 24 | Enhancement of oxaliplatin-induced colon cancer cell apoptosis by alantolactone, a natural product inducer of ROS. Int J Biol Sci. 2019 Jun 4;15(8):1676-1684. doi: 10.7150/ijbs.35265. | Click |
| 25 | Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance. Cancer Sci. 2018 Jan;109(1):94-102. doi: 10.1111/cas.13425. | Click |
| 26 | Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Asian Pac J Cancer Prev. 2014;15(6):2911-6. doi: 10.7314/apjcp.2014.15.6.2911. | Click |
| 27 | β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. Sci Rep. 2016 Feb 12;6:21010. doi: 10.1038/srep21010. | Click |
